Overview

Avastin in Combination With Temozolomide for Unresectable or Multifocal GBMs and Gliosarcomas

Status:
Completed
Trial end date:
2012-05-01
Target enrollment:
Participant gender:
Summary
Primary objective- To determine efficacy of Avastin, 10 mg/kg every other week, in combination with standard 5-day temozolomide in terms of response rate. Secondary objective- To determine safety of Avastin & Temozolomide in unresectable glioblastoma patients
Phase:
Phase 2
Details
Lead Sponsor:
Duke University
Collaborators:
Genentech, Inc.
Schering-Plough
Treatments:
Bevacizumab
Dacarbazine
Temozolomide